Accra has turned down a sweeping health partnership with Washington, citing concerns over medical data access, pathogen information, and restrictions on drug oversight. The move has reignited a broader conversation about Africa’s health sovereignty.
Accra — Ghana has raised a question that extends far beyond the borders of its health system: what is the true price of a nation’s sovereignty when foreign aid comes with sensitive conditions?
For Accra, the answer is clear: not $109 million.
The Ghanaian government has rejected a proposed health agreement with the United States that would have provided approximately $109 million in American funding over five years. The overall package was valued at around $300 million, factoring in expected complementary contributions from Ghana.
President John Dramani Mahama confirmed and explained the rejection during an appearance at the Council on Foreign Relations in New York on September 25.
And his words struck a chord.
“Who takes another country’s medical records?”
According to the Ghanaian president, the draft agreement included provisions for transmitting Ghana’s pathogen profiles and medical data to the United States. He also stated that the text imposed a counterpart funding requirement on Ghana and contained clauses regarding control over medical products entering the country.
For Mahama, these conditions were simply “humiliating.”
🔴 What Washington was actually asking for
The affair deserves a closer look beyond the headline-grabbing quote.
Ghana did not reject a $100 million package simply because it came from the United States. The problem lies in the conditions attached to the funding.
The Associated Press reported in May that the draft agreement, with a total value of around $300 million, would have brought Ghana approximately $109 million over five years. Arnold Kavaarpuo, executive director of Ghana’s Data Protection Commission and a participant in the negotiations, indicated that certain provisions would have allowed access to sensitive health data under circumstances that could potentially identify individuals. According to him, the scope of this access went well beyond what is typically necessary.
The BMJ also reported that the Ghanaian draft included access to health data and pathogens for 16 American companies. The journal noted, however, that several clauses in the new US health agreements remain difficult to examine publicly, as not all negotiated texts have been made public.
This is where nuance is needed: it would be excessive to claim that the United States was demanding unrestricted access to “all Ghanaians’ medical data.” What is documented, however, are Ghanaian concerns about the extent of access to health data and pathogen information.
🧬 Why is this data so important?
Behind medical records lies a genuine question of power.
Health data reveals which diseases are circulating, where they are spreading, which populations are most exposed, and how epidemics are evolving.
Pathogen data can also have considerable scientific value. It can contribute to research on vaccines, treatments, and surveillance of emerging epidemics.
This is precisely what is fueling concerns among several African governments.
In February 2026, Jean Kaseya, director-general of the Africa Centres for Disease Control and Prevention (Africa CDC), had already expressed serious concerns about provisions related to data and pathogen sharing in the new US health agreements. Reuters reported at the time that some agreements required rapid sharing of sensitive data without guaranteeing African countries access to treatments or vaccines that might result from that information.
Ghana is therefore not an isolated case.
🇬🇭 Accra no longer wants to rely entirely on foreign aid
The rejection also comes in a particular context.
Since the suspension of a large portion of US aid programs, Ghana has been seeking to reduce its dependence on external funding. In February 2025, the Ghanaian presidency had already estimated the shortfall caused by the suspension of USAID funding at $156 million, with $78.2 million directly affecting essential health programs.
The Mahama government is now pushing the idea of “health sovereignty.”
This orientation was reinforced in September with the launch of the report A Sovereign Future for Health, presented as part of the Accra Reset initiative. The document proposes, among other things, reducing Southern countries’ dependence on external funding and strengthening their own health systems.
Accra’s message is therefore relatively clear: Ghana wants to continue working with its foreign partners, but on the basis of agreements it considers more balanced.
💊 Another point of friction: medicines
The other element revealed by Mahama is particularly sensitive.
According to the president, the draft agreement provided that certain medicines and medical products supplied under the program would not be subject to controls by Ghana’s Food and Drugs Authority (FDA).
This claim has not been publicly confirmed in detail by the US government, which, when asked by the Associated Press, said it does not comment on the details of bilateral negotiations.
But if this provision does match the text presented to the Ghanaian government, it explains part of Accra’s firmness: for the authorities, health funding should not lead to reducing the national regulator’s ability to control medical products used on its territory.
🇺🇸 And the American response?
Washington has not publicly detailed the contested clauses.
A US State Department spokesperson said the United States does not disclose details of bilateral negotiations, while asserting that Washington is still looking for ways to strengthen its partnership with Ghana.
This absence of full publication of the text therefore prevents settling certain essential questions.
What data would exactly have been accessible?
To which American companies or institutions?
Under what circumstances could individuals have been identified?
What would have been the data retention period?
What legal guarantees would have protected Ghanaian patients?
On these points, public information remains incomplete.
🌍 Ghana opens a debate that goes beyond Ghana
The real issue in this affair may be precisely there.
For decades, many African health systems have depended on funding, medicines, equipment, and programs from abroad. These partnerships have saved lives and fought major diseases.
But the digital transformation of health is now changing the nature of cooperation.
Aid no longer concerns only money, medicines, or equipment. It can also give access to a strategic resource: data.
And Ghana has just reminded everyone that it intends to retain control of that resource.
John Mahama states that his government rejected the draft after its review by the Ministry of Health and its passage before the Cabinet. He also says the decision had the support of the entire government and that the rejection was decided very quickly.
Ghana will now have to demonstrate that it can fill the abandoned funding gap without compromising its health programs.
But for Accra, the choice seems deliberate:
better to seek other partners than to conclude an agreement the government considers incompatible with health sovereignty and the protection of Ghanaians’ data.
The question Ghana is now asking its foreign partners is simple:
When Africa receives aid to care for its populations, must it also surrender control over information about those populations?
The debate is probably only just beginning.
